Axatilimab for Refractory Chronic Graft-vs-Host Disease After Failure of at Least Two Prior Systemic Therapies
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Axatilimab for Chronic Graft-Versus-Host Disease After Failure of at Least Two Prior Systemic Therapies: Results of a Phase I/II Study
J. Clin. Oncol 2022 Dec 02;[EPub Ahead of Print], CL Kitko, M Arora, Z DeFilipp, MA Zaid, A Di Stasi, V Radojcic, CB Betts, LM Coussens, ML Meyers, H Qamoos, P Ordentlich, V Kumar, C Quaranto, A Schmitt, Y Gu, BR Blazar, TP Wang, A Salhotra, I Pusic, M Jagasia, SJ LeeFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.